A biotechnology target and lead discovery and optimization company, Serometrix is delivering better answers by asking better questions. Seeking a way to shorten development times and improve yields, the company developed SimPep™, the company's in silico discovery platform, to probe nature in novel ways to:

• Identify relevant protein-protein interaction sites critical to regulating pathways integral to biological conditions of commercial interest
• Emulate these highly evolved human regulatory sequences (7-10 amino acids) in confirmatory in vitro assays
• Optimize these novel hits using structure based optimization techniques

Utilizing this platform, Serometrix harnesses the clinically predictive power inherent within the human system; the only rational approach that promises to immediately and dramatically enhance productivity in drug development.